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The discovery of cancer-associated alterations has
primarily focused on genetic variants. Nonetheless,
altered epigenomes contribute to deregulate tran-
scription and promote oncogenic pathways. Here,
we designed an algorithmic approach (RESET) to
identify aberrant DNA methylation and associated
cis-transcriptional changes across >6,000 human tu-
mors. Tumors exhibiting mutations of chromatin re-
modeling factors and Wnt signaling displayed DNA
methylation instability, characterized by numerous
hyper- and hypo-methylated loci. Most silenced and
enhanced genes coalesced in specific pathways
including apoptosis, DNA repair, and cellmetabolism.
Cancer-germlineantigens (CG)were frequentlyepige-
nomically enhanced and their expression correlated
with response to anti-PD-1, but not anti-CTLA4, in
skin melanoma. Finally, we demonstrated the poten-
tial of our approach to explore DNA methylation
changes inpediatric tumors,which frequently lackge-
netic drivers and exhibit epigenomic modifications.
Our results provide a pan-cancer map of aberrant
DNAmethylation to inform functional and therapeutic
studies.INTRODUCTION
The cell epigenome provides a fundamental infrastructure to co-
ordinate spatiotemporal gene expression and cell-type-specific
patterns (Shen and Laird, 2013). This organization ranges from
directly decorating DNA molecules and histone proteins (Jones,
2012; Zhou et al., 2011) to shaping long-range DNA contacts be-
tween regulatory elements (Bonev and Cavalli, 2016; Fatica and
Bozzoni, 2014; Long et al., 2016). Acting through multiple hierar-
chical layers, epigenetic modifications enable and repress tran-
scription and stably determine cell identity. Cancer cells exhibit
profound modifications of this epigenetic infrastructure (Baylin1066 Cell Reports 25, 1066–1080, October 23, 2018 ª 2018 The Auth
This is an open access article under the CC BY-NC-ND license (http://and Jones, 2011; Esteller, 2008), starting from its foundation,
DNA methylation (Esteller, 2007; Klutstein et al., 2016). Aberrant
DNA methylation in cancer has primarily been observed in the
form of global hypo-methylation within intergenic regions, espe-
cially those enriched for Alu and LINE-1 repeats (Ehrlich, 2009),
punctuated by hyper-methylation of CpG dense regions,
referred to as CpG islands (CGI). Unlikemost of DNA hypo-meth-
ylated regions, hyper-methylated CGI are frequently located at
gene promoters and have been associated with silencing of tu-
mor suppressors (Esteller, 2007) and incomplete differentiation
(Widschwendter et al., 2007), directly linking DNA methylation
changes to oncogenic transformation. In turn, the development
of pharmacological inhibitors of DNA methylation has provided
novel therapeutic opportunities (Swisher et al., 2017).
Aberrant DNA methylation in human cancers has mostly been
investigated through two main approaches: (1) analysis of global
DNAmethylation patterns (Noushmehr et al., 2010; Toyota et al.,
1999) and differentially methylated regions (Amabile et al., 2015),
and (2) identification of mRNA silencing of genes of interest by
hyper-methylation (Esteller, 2007; Cancer Genome Atlas
Research Network, 2012). The first approach has gained
momentum with the application of high-throughput arrays to
thousands of human tumors. Importantly, clustering of cancer
samples based on variably DNA methylated loci led to the iden-
tification of molecularly and clinically relevant subtypes, most
notably tumors characterized by frequent hyper-methylation at
CGI, also known as CpG island methylator phenotype (CIMP)
(Issa, 2004). Recurrently hyper-methylated loci in cancer were
found enriched for polycomb targets involved in cell differenti-
ation, thus likely to sustain a stem cell phenotype (Widsch-
wendter et al., 2007), and associated with a mitotic signature
upregulated in cancer and pre-cancerous lesions (Yang et al.,
2016). The oncogenic role of specific targets within hyper-meth-
ylated regions has been highlighted by targeted profiling of
known and candidate tumor suppressors. Gene silencing by
promoter hyper-methylation have been found for established
cancer genes, such as VHL (Herman et al., 1994) and CDKN2A
(Cancer Genome Atlas Research Network, 2012) and has pro-
vided markers of therapeutic response, such as for MGMT
(Weller et al., 2010) andBRCA1 (Cancer Genome Atlas Research
Network, 2011). More recently, unbiased approaches have beenor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. RESET Identifies Hyper- and Hypo-Methylation Events across Human Cancers
(A) Schematic pipeline of the first step of the RESET algorithm.
(B and C) Hyper-methylation (B) and hypo-methylation (C) event frequencies in 6,010 human tumors (black dots) across 23 cancer types. Frequencies are
estimated as the percentage of probes found hyper-methylated (hypo-methylated) compared to normal tissues. Tumor types are sorted by increasing hyper-
methylation (hypo-methylation) mean frequency. Molecular subtypes associated with hyper-methylation (hypo-methylation) event frequencies are shown at the
bottom (p value < 0.05), samples are sorted by aberrant methylation frequency, samples with the indicated annotation are color-coded, otherwise they are left
white).
(legend continued on next page)
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proposed to analyze DNAmethylation changes in cancer. Exam-
ples are methods integrating multiple data types to study hyper-
methylation within pathway modules (Jiao et al., 2014) or
develop cancer risk predictors (Teschendorff et al., 2012).
Finally, explorations of silenced genes by DNA hyper-methyl-
ation have utilized statistical tests to assess gene expression dif-
ferences between methylated and unmethylated tumors in an
unbiased and systematic way (Hinoue et al., 2012; Sepulveda
et al., 2016; Cancer Genome Atlas Network, 2015). However,
these approaches often suffer from sample size biases that favor
frequently altered genes (see STARMethods), and have focused
on silencing events within specific tumor types.
Overall, in contrast to systematic pan-cancer investigations of
genetic alterations (Bailey et al., 2018; Beroukhim et al., 2010;
Lawrence et al., 2013), analyses of aberrant DNA methylation
and associated transcriptional changes have so far largely
been limited to specific tumor types or genes of interest. As
such, several questions remains outstanding: How does the
extent of aberrantly methylated loci compare among different tu-
mor types?Which genes and pathways are frequently aberrantly
methylated? How genetic alterations and DNA methylation
events associate in cancer? And what are the functional and
therapeutic implications of such alterations? Here, we explore
these questions by systematically and unbiasedly investigating
the genetic, DNA methylation, and transcriptomic profiles of
more than 6,000 human tumors (Table S1), using a newly de-
signed algorithmic approach.
RESULTS
To systematically identify candidate functional DNA methylation
changes in cancer, we (1) first, identify gene transcription start
sites with aberrant methylation states in cancer samples
compared to normal tissue (hyper- and hypo-methylation calling)
and (2) second, we query whether aberrant methylation states
associate with silenced or enhanced mRNA expression of the
corresponding genes (silencing and enhancing events identifica-
tion). This two-step approach models the distributions of DNA
methylation at specific loci in normal and tumor samples and
quantifies the strength (or effect size) of the associations be-
tween DNA methylation and mRNA expression changes (see
STAR Methods). Our computational algorithm is thus a resource
to detect epigenetically silenced and enhanced targets in cancer
(RESET). In the following, we will separately present the results
associated to each step (1 and 2) and, unless stated otherwise,
the term ‘‘epigenetic’’ will be used to connotate processes asso-
ciated to DNA methylation.(D) We tested 505 genetic alterations for their association with increased hyp
FDR q values are reported as –log10(q) and significant associations (q < 0.01) are
cytoband for amplifications (A) and deletions (D). Candidate targets of focal amp
ACC, adrenocortical carcinoma; AML, acute myeloid leukemia; BLCA, bladde
luminal/B. luminal, luminal breast invasive carcinoma; CESC, cervix squamous
noma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell car
carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, low grade glioma; L
squamous cell carcinoma; OV, ovarian carcinoma; PRAD, prostate adenocarci
THCA, thyroid papillary carcinoma; UCEC, uterine corpus endometrial carcinoma
available in Table S1.
See also Figure S1 and Table S2.
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Types
We applied RESET to 23 cancer cohorts (Table S1) molecularly
profiled by The Cancer Genome Atlas (TCGA) for a total of
6,010 human tumors with available DNA methylomes gener-
ated by the Illumina Infinium HM450 array. For 5,633 samples,
we had matched RNA-sequencing data. In addition, we sepa-
rately analyzed a cohort of 600 serous ovarian tumors that
were profiled by TCGA using the HM27 array, 265 of which
were analyzed by RNA-sequencing. To estimate the methyl-
ation status in normal conditions, we collected DNA methyl-
ation data for 702 normal tissue samples from 14 TCGA cancer
cohorts. In this study, we focused on pan-cancer DNA methyl-
ation events and, thus, we studied only probes that exhibited
a consistently high or low methylation status across all the
normal tissues that we analyzed (Figures S1A and S1B). Probes
were further filtered to include only those proximal to gene
transcription start sites (TSS probes) (Figures S1C–S1H;
STAR Methods). In total, we identified 64,414 probes—map-
ping to 12,053 genes—that have low DNA methylation across
all normal samples, and 3,423 probes—mapping to 2,006
genes—that have high DNA methylation across all normal sam-
ples (Table S2).
The fractions of hyper- and hypo-methylated TSS probes
determined by RESET (step 1, Figure 1A) varied across tumor
types and were associated with molecular subtypes (Figures
1B, 1C, and S1I for ovarian cancer). Our results recapitulated
known associations between recurrent hyper-methylation and
tumor subtypes characterized by IDH1 (R132) and IDH2 (R140
and R172) mutations in glioma (Noushmehr et al., 2010), micro-
satellite instability (MSI) in uterine, colorectal, and stomach can-
cers (Cancer Genome Atlas Network, 2012; Kandoth et al., 2013;
Cancer Genome Atlas Research Network, 2014), and viral infec-
tion (EBV) in stomach cancer (Figure 1B). Conversely, IDH-wild-
type glioma and HPV-negative cervical tumors exhibited high
percentages of hypo-methylated loci. Interestingly,MSI stomach
tumors also exhibited a significantly higher percentage of hypo-
methylated loci than micro-satellite stable tumors (Figure 1C).
Overall, the fraction of aberrantly methylated probes did not
correlate with tumor purity, ploidy, or infiltration of specific
immune cell populations (Figure S2A; Table S2). Instead, the
fraction of hypo-methylated probes correlated with a recently
proposed stemness signature based on hypo-methylation of
specific loci (Malta et al., 2018) and with the extent of chromo-
somal alterations in lung, prostate, stomach, and uterine carci-
noma, supporting a link between DNA hypo-methylation and
chromosomal instability (Gaudet et al., 2003).er- (top) and hypo-methylation (bottom) within each tumor type. Wilcoxon
color-coded (blue/red) and labeled by gene symbol for somatic mutations or
lifications and deletions are reported in brackets.
r carcinoma; BRCA basal/B. basal, basal breast invasive carcinoma; BRCA
cell carcinoma; CRC, colon and rectum carcinoma; ESCA, esophageal carci-
cinoma; KICH, kidney chromophobe carcinoma; KIRC, kidney renal clear cell
IHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung
noma; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma;
; UCS, uterine carcinosarcoma. The number of samples for each tumor type are
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Figure 2. DNA Methylation Instability
(A and B) Comparison of rank positions obtained by each tumor type with respect to hyper-methylation (top) or hypo-methylation (bottom) event frequencies.
(A) For 19 tumor types the rank positions based on hyper- and hypo-methylation shift by at most 8 positions (corresponding to one-third of the total) showing a
high rank correlation (Spearman’s correlation = 0.74, p = 0.0005). These 19 cancer types were grouped into cancers with low, medium, and high aberrant
methylation frequency, as indicated by the color key.
(B) Only 5 tumor types scored at the top of one rank and at the bottom of the other.
(legend continued on next page)
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Next, we tested a set of 505 recurrent genetic alterations in
cancer (Mina et al., 2017) for association with aberrant DNA
methylation (Table S2). Many of the alterations that scored as
significant (q < 0.01) were reported enriched in the molecular
subtypes highlighted above. These include IDH1, CIC, and
NOTCH1 mutations in glioma, which characterize IDH mutant
tumors with 1p/19q co-deletion (Brat et al., 2015), BRAF muta-
tions in MSI colorectal cancer (Cancer Genome Atlas Network,
2012), and PIK3CA and ARID1A mutations in EBV+ stomach
tumors (Cancer Genome Atlas Research Network, 2014) (Fig-
ure 1D). Significant associations with hypo-methylation events
were found for NSD1 mutations in head and neck cancer,
BRAF mutations in thyroid carcinoma, and alterations associ-
ated with chromosomal instability, such as CDKN2A deletions
in glioma and papillary kidney tumors, and TP53 mutations and
copy number amplifications in stomach and uterine cancer
(Figure 1D). The latter were consistent with the observed corre-
lation between the fraction of hypo-methylated probes and chro-
mosomal instability in these tumor types (Figure S2A).
The majority of tumor types (19 out of 24) with low (high) mean
hyper-methylation frequency also exhibited low (high) mean
hypo-methylation frequency (Figure 2A, Spearman rank correla-
tion = 0.74, p = 0.0005). Notable exceptions were low grade gli-
oma (LGG) and acute myeloid leukemia (AML), which were both
enriched for IDH1/2 mutations and hyper-methylated loci (Fig-
ure 2B). A considerable number of samples exhibited high
numbers of both hyper- and hypo-methylated TSS probes (Fig-
ure 2C). We refer to these samples as characterized by DNA
methylation instability (DMI), to distinguish them from cases
where only hyper-methylation or hypo-methylation is frequent.
We scored the extent of DMI in each sample by combining the
percentages of hyper- and hypo-methylated loci using the
F2-measure (color-coded in Figure 2C). DMI scores did not corre-
late with tumor purity, ploidy, or immune infiltration (Figure S2B).
Using these scores, we assessed the association between
recurrent genetic alterations and DMI, both within each tumor
type and at a pan-cancer level (Table S3). The two analyses
concordantly identified a set of recurrent mutations as enriched
in samples with high DMI scores (Figure 2D). DMI-associated
mutated genes were enriched for chromatin remodeling factors
(p = 4.2E8, false discovery rate [FDR] <2E4, Table S3), such
as H3K36 methyltransferases NSD1 and SETD2, SWI/SNF com-
ponents ARID2 and ARID1B, and lysine methyl-transferases
KMT2C and KMT2D. Additionally, alterations of Wnt signaling
were significantly associated with DMI (p = 3.3E4, FDR <0.05),
especiallymutations of b-catenin (CTNNB1) and theWnt-inhibitor
RNF43. These mutations were previously found associated with
micro-satellite instability (MSI) in gastric tumors (Cancer Genome
Atlas Network, 2012; Cancer Genome Atlas Research Network,(C) Percentage of probes in each tumor sample that are hyper- (x axis) and hypo-m
(DMI) score (see STAR Methods).
(D)We tested 505 genetic alterations for their association with DMI scores both wit
Wilcoxon p value) and at a pan-cancer level (y axis, ANOVAp value). Alterations sig
green, amplifications in red) and labeled as in Figure 1D.
(E) Normalized fraction of hyper- (H) and hypo-methylated (h) probes in low grad
stomach adenocarcinoma (STAD). The following tumor subtypes are highlighted:
AML samples with IDH1 (yellow) and IDH2 (brown) mutations, EBV-positive STAD
See also Figure S2 and Table S3.
1070 Cell Reports 25, 1066–1080, October 23, 20182014), in apparent contradiction with reported associations be-
tween MSI and CIMP (Hinoue et al., 2009). This observation
prompted us to re-evaluate tumors subtypes in the TCGA cohort
that were previously classified CIMP. Tumors with IDH1/2muta-
tions (IDH mutant) and EBV-positive stomach adenocarcinoma
were characterized by high fractions of hyper-methylated and
low fractions of hypo-methylated TSS probes (Figure 2E).
Conversely, MSI tumors and FHmutant renal papillary carcinoma
exhibited high fractions of both hyper- and hypo-methylated TSS
probes (Figures 2E and S2C). These results indicate that, by ac-
counting for both aberrant hyper- and hypo-methylation, we can
distinguish between ‘‘pure’’ CIMP (i.e., tumors exhibiting highly
recurrent hyper-methylation of gene TSS but not hypo-methyl-
ation), and tumors characterized by DMI (i.e., frequent hyper
and hypo-methylation of gene TSS).
Epigenetically Silenced and Enhanced Targets across
24 Human Cancers
RESET was run independently in each of the 24 cancer cohorts
(Figure 3A), and genes scoring as significant in at least one tumor
type were retained and ranked based on the sum of their signifi-
cant scores (Figures 3B and 3C; Table S4). In total, we identified
581 epigenetically silenced and 85 epigenetically enhanced
genes (Figures 3B and 3C). Silenced targets included previously
reported targets of recurrent hyper-methylation such as MLH1,
BRCA1, FANCF, and CHFR (Lahtz and Pfeifer, 2011; Cancer
Genome Atlas Research Network, 2011; Cancer Genome Atlas
Network, 2012; Toyota et al., 2003) and other cancer-associated
genes including the cell-cycle-regulatorCDKN1C, the transform-
ing growth factor b (TGF-b) signaling genes TGIF1 and ACVR1C,
and the pro-apoptotic genes FAS, BIRC3, TNFRSF1A, and
TNFRSF10A. Similarly, epigenetically enhanced targets included
positive controls such as MAGEC2 (Van Tongelen et al., 2017)
and SYCP2 (Degli Esposti et al., 2017), and known oncogenes,
such asMYCN, BCL2L10, CTNNB1, IRS2, and IGF2. Only 3 out
of 581 silenced and 3 out 85 enhanced target genes showed sig-
nificant associations between their alteration patterns and the
estimated fraction of infiltrated non-tumor cells (q value <0.1,
fold-change >1.5, Table S4) and, for each gene, this association
was found only within one tumor type.
The roster of silenced and enhanced targets identified by
RESET included several genes whose roles in cancer are still
largely unexplored, such as PXMP4 and PNLDC1, that scored
as significant across multiple tumor types (Figures 3D and 3E).
PXMP4 is a peroxisome component and was previously shown
to become silenced in an androgen-insensitive prostate cancer
subline (AI-LnCAP), whereas its transient re-activation was able
to impair cell proliferation (Wu and Ho, 2004). Here, PXMP4
was found to be hyper-methylated and silenced in 8 tumor types,ethylated (y axis). Samples are color-coded by their DNAmethylation instability
hin each single tumor type (top scoring association for each event on the x axis,
nificant in both tests (FDR <0.1 for both analyses) are color-coded (mutations in
e glioma (LGG), acute myeloid leukemia (AML), colorectal cancer (CRC), and
LGG IDH mutant (yellow) and LGG IDH-mut with 1p/19q co-deletion (brown),
(black), and STAD and CRC tumors with micro-satellite instability (MSI, pink).
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Figure 3. Epigenetic Silencing and Enhancing Events in Cancer
(A) Schematic pipeline of the complete RESET algorithm. The first step (shaded panel on the left) performs aberrant DNA methylation calling, the second step
(highlighted panel on the right) identifies epigenetically silenced and enhanced genes.
(B and C) RESET identifies 581 epigenetically silenced genes (B) and 85 epigenetically enhanced genes (C) across the pan-cancer dataset. Genes are ranked
based on the sum of scores obtained in each tumor type and color-coded based on the number of cancer types where they scored as significant (shades of blue
for silenced, shades of red for enhanced). Representative silenced and enhanced targets are labeled by their official gene symbol.
(legend continued on next page)
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with incidences varying between 3% (skin melanoma) to 31%
(endometrial cancer) (Figure 3D). PNLDC1 encodes for a deade-
nylase enzyme expressed in mouse embryonic stem cells and
suppressed byDNAmethylation during cell differentiation (Anas-
tasakis et al., 2016). PNLDC1 was altered in 9 tumor types, with
incidences varying from 1% (luminal breast cancer) to 22%
(head and neck carcinoma) (Figure 3E). Both genes are thus
altered across multiple tumor types, albeit only epigenetically,
and are associated with potential oncogenic pathways such as
cell proliferation and differentiation.
To support the association between aberrant DNAmethylation
andmRNA expression for our set of epigenetically altered genes,
we analyzed colorectal and lung cancer cell lines that were pro-
filed by RNA-sequencing before and after treatment with the
DNA-demethylating agent 50azacitidine (50AZAdC). In all cases,
the vast majority of RESET-targets (n = 581) that were methyl-
ated in the analyzed cell lines increased expression upon treat-
ment with 50AZAdC (Figure S3D). Next, we selected 4 top scoring
genes (PXMP4 and H2AFJ among silenced targets, PNLDC1
and SYCP2 among enhanced targets) and verified their methyl-
ation and expression status in a broader panel of cancer cell lines
(Iorio et al., 2016). Reported mRNA expression of these genes
was negatively correlated with promoter DNA methylation (Fig-
ures 3F, 3H, and S3F). We validated mRNA levels of the 4 genes
by quantitative PCR (qPCR) (Figure S3G) and re-assessed them
after 7 days of treatment with 50AZAdC. The treatment restored
expression of all tested genes in the cell lines where they were
silenced, and this effect wasmore pronounced in cell lines where
the targets exhibited the most extreme DNA methylation and
transcriptional downregulation (Figures 3G, 3I, and S3H). These
results indicate that RESET can identify bona fide epigenetically
regulated genes in cancer.
Interdependencies between Genetic and Epigenetic
Events
Out of the 581 silenced and 85 enhanced targets identified by
RESET, only a handful had been previously found as recurrently
mutated,deleted,oramplified incancer (Minaet al., 2017) (Figures
4A and 4B). A few targets in our datasets exhibited patterns of co-
occurrence between promoter hyper-methylation and loss of het-
erozygosity, among which genes in chromosomes 1p and 19q,
which are frequently deleted in IDH mutant LGG. These included
the candidate tumor suppressors CD58 (Challa-Malladi et al.,
2011) andEMP3 (Alaminos et al., 2005) that exhibited significantly(D) PXMP4 mRNA expression (y axis) is compared in epigenetically silenced (b
epigenetic silencing of PXMP4 was significant.
(E) PNLDC1 mRNA expression (y axis) is compared in epigenetically enhanced
epigenetic enhancement of PNLDC1 was significant.
(F) DNA methylation (x axis) and mRNA expression (y axis) of PXMP4 in 6 cancer c
gene and summarized by boxplots.
(G) Relative PXMP4 expression measured by qPCR in cell lines with high methyla
(black filled bars) compared to untreated cells (black contoured bars).
(H) DNAmethylation (x axis) andmRNA expression (y axis) of PNLDC1 in 3 cancer
gene and summarized by boxplots.
(I) Relative PNLDC1 expression measured by qPCR in cell lines with high methyla
(black filled bars) compared to untreated cells (black contoured bars).
In all the analyses, qPCR experiments were repeated three times and averaged.
See also Figure S3 and Table S4.
1072 Cell Reports 25, 1066–1080, October 23, 2018lower expression when copy number losses were accompanied
by promoter hyper-methylation (Figures S4A and S4B). Similarly,
we found synergistic CTNNB1 upregulation in cervical carci-
nomas with concurrent promoter hypo-methylation and gain-of-
function mutations (Figure S4C). Within each tumor type, genetic
alterations associated with specific molecular subtypes (e.g.,
MSI, CIN, EBV+, and IDH mutant gliomas) were associated with
an increased number of epigenetic silencing and/or enhancing
events (Figure 4C; Table S5). To correct for tumor types and sub-
types, we assessed co-occurrence and mutual exclusivity be-
tween genetic and epigenetic alterations within the pan-cancer
cohort using the SELECT algorithm (Mina et al., 2017) (Table S5).
BRAFmutations were found frequently mutually exclusive with
multiple silencing events (Figure 4D), especially occurring in skin
melanoma, whereas, IDH1mutations co-occurred with the high-
est number of epigenetic silencing events (Figure 4E). Silenced
genes co-occurrent with IDH1mutations included several meta-
bolic regulators involved in oxidation-reduction processes
(p value = 1.8E5) and nicotinamide adenine dinucleotide
(NAD) cycle (Chiarugi et al., 2012), such as NMRAL1, ACADS,
CYB5R1, and NMNAT3. The latter two were also concurrent
with IDH2 mutations. In addition, silencing of the candidate tu-
mor suppressors HTATIP2 (Dong et al., 2015) and SH2D4A
(Ploeger et al., 2016) (Figure 4F) was co-occurring with IDH1mu-
tations in both glioma and melanoma. Interestingly, mutations of
CTNNB1 and NSD1 were significantly associated with DMI (Fig-
ure 2D) and, consistently, co-occurrent with both silencing and
enhancing events (Figure 4E). CTNNB1 was significantly co-
occurrent with 5 enhancing and 10 silencing events (Figure 4G),
most of them prevalent in liver hepatocellular carcinoma and tar-
geting Wnt-related genes. These included enhanced expression
of the glutamine synthetaseGLUL, a direct Wnt and Hippo target
(Cox et al., 2016; Lachenmayer et al., 2012), and of the synovial
sarcoma associated gene SSX1, recently implicated in Wnt-
target activation (Cironi et al., 2016). Similarly, the Wnt repressor
NPHP4 (Borgal et al., 2012) was found frequently silenced in
CTNNB1 mutant tumors. In addition, CTNNB1 mutations signif-
icantly co-occurred with silencing of the heat-shock factor
DNAJA4 in skin melanoma, liver, adrenocortical, and stom-
ach carcinoma. DNAJA4 has been shown to promote ApoE
expression, which in turn suppresses invasion and metastasis
in melanoma (Pencheva et al., 2012). These results suggest
DMI is associated with both the emergence and selection of
epigenetic alterations promoting oncogenic processes.lue-contoured dots) and wild-type (gray dots) cases in 8 tumor types where
(red-contoured dots) and wild-type (gray dots) cases in 9 tumor types where
ell lines. DNA methylation values are reported for each probe that maps to the
tion of PXMP4 is strongly enhanced upon treatment with 50AZAdC for 7 days
cell lines. DNAmethylation values are reported for each probe that maps to the
tion of PNLDC1 is strongly enhanced upon treatment with 50AZAdC for 7 days
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Figure 4. Interdependencies between Genetic and Epigenetic Alterations
(A and B) Gene targets of epigenetic silencing (blue contoured circle, A) and enhancing (red contoured circle, B) events are intersected with gene targets of
recurrent somatic mutations (green circles), copy number deletions (blue circle, A) and copy number amplifications (red circle, B).
(C) We tested 505 genetic alterations for their association with the incidence of epigenetic silencing (top) and enhancing (bottom) events within each tumor type.
Wilcoxon FDR q values are reported as –log10(q) and significant associations (q < 0.01) are color-coded (blue/red) and labeled as in Figure 1D.
(D and E) Using SELECT, we tested 505 recurrent genetic alterations in cancer for mutual exclusivity and co-occurrence with our set of 581 epigenetic silencing
and 85 enhancing events in cancer. Genetic alterations that are mutually exclusive (D) or co-occurrent (E) with multiple epigenetic silencing (blue) or enhancing
(red) events. Genetic alterations are ranked by the sumof SELECT scores and the actual number of significant associations found by SELECT are reported (# hits).
Genetic alterations are labeled as in Figure 1D.
(F and G) Co-occurrence (left) and mutual exclusivity (right) interactions between IDH1 (F) or CTNNB1 (G) and silencing and enhancing events. Significant events
(above the red dotted line) are color-coded (silencing events, blue contoured dots; enhancing events, red contoured dots) and representative targets are labeled.
See also Figure S4 and Table S5.Cancer Pathways Affected by Epigenetically Silencing
and Enhancing Events
Functional enrichment analysis performed on epigenetically
silenced genes found transcriptional regulation, apoptosis, andcell metabolism as the most enriched categories (Figure 5A;
Table S4). In addition, frequently methylated polycomb targets
(Widschwendter et al., 2007) were also moderately enriched
within our set of silenced genes (p value = 0.025). In contrast,Cell Reports 25, 1066–1080, October 23, 2018 1073
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epigenetically enhanced geneswere highly enriched for germcell
development, corresponding to a high presence of cancer-germ-
line (CG) antigen genes (CG genes), as well as cell proliferation
and chromatin organization, both associated with epigenetic
enhancing of oncogenes and transcriptional regulators such as
MYCN, CTNNB1, and IGF2 (Figure 5B).
Cell metabolism is characteristically altered in most cancers
(Cairns et al., 2011), and mutations of the isocitrate dehydroge-
nases IDH1 and IDH2 establish a critical link between altered
metabolic processes and increased DNA methylation (Lu and
Thompson, 2012). IDH-mutations in our dataset characterized
77% of LGG, and LGG tumors exhibited the highest incidence
of silenced metabolic genes. However, most of these silencing
events were rarely found in other tumor types (Figure 5C). The
majority of metabolic genes that were silenced across multiple
tumor types were associated with mitochondrial reactive oxygen
species (ROS) generation including a broad class of dehydroge-
nases, inhibitors of H2O2, and components of the electron trans-
port chain (ETC) (Figures 5C and 5D). Because the predicted
downstream effect of silencing these targets is an increased
generation of ROS, we scored each tumor using (1) an mRNA
expression signature derived from silenced mitochondrial ROS
genes identified by RESET, and (2) an experimentally derived
signature composed of genes overexpressed upon H2O2 induc-
tion (Parikh et al., 2010). Scores from these signatures were
significantly anti-correlated in almost all tumor types, supporting
the association between silencing of ROS inhibitors and genera-
tion of mitochondrial ROS (Figure 5E).
CG antigens, or CG-genes, are predominantly expressed in
germ cells and trophoblasts, but upregulated in tumors by epige-
netic mechanisms (Simpson et al., 2005) (Figure S5A). Not all tu-
mor types presented an equal extent of upregulated CG-genes,
which were either enhanced across multiple cancers or specif-
ically in a single tumor type (Figure S5B). While their oncogenic
role remains unclear (Simpson et al., 2005), CG antigens have
been recognized as highly immunogenic and have been identi-
fied as targets of antitumor T cell immune response in patientsFigure 5. Cancer Pathways Affected by Epigenetic Silencing and Enha
(A) Gene Ontology (GO) categories significantly enriched (FDR q-value on the y
on 3 main groups: metabolism and ROS generation, apoptosis, and transcription
(B) GO categories significantly enriched (FDR q-value on the y axis) for epigenetic
cancer-germline (CG) antigens, cell proliferation, and chromatin organization.
(C) Frequency of silencing genes involved in the ROS generation pathway segreg
activity (annotated on the right) that can be grouped into dehydrogenases (blu
transport chain (ETC, dark blue), and hypoxia inhibitors (blue contoured).
(D) Pathway schematic of mitochondrial ROS generation highlighting the function
(E) Correlation between a gene expression signature composed of genes overexp
silenced targets involved in mitochondrial ROS generation (x axis). The two signat
tumor types (here represented by blue dots with size proportional to the inciden
(F) Normalized mean expression differences (y axis) of CG- and CG-like genes (
(CR, complete responders; PR, partial responders; PD, progressive disease). CG
RESET in the TCGA melanoma cohort. mRNA expression differences come from
anti-PD-1 therapeutic antibody. Expression differences are normalized as the sum
values in PD cases divided by the total sum of expression values.
(G) Comparison of CG signature scores betweenmelanoma patients with a progre
dots) or a complete response (CR, red-filled dots) to anti-PD-1.
(H) Overall survival of melanoma patients treated with anti-PD-1. Patients were pa
high scores (score >0.5, red line) showing significant better survival than those w
See also Figure S5 and Table S4.receiving tumor-infiltrating adoptive T cell therapy (Stevanovic
et al., 2017). To assess the prognostic value of epigenetically
enhanced CG-genes, we collected mRNA expression data for
a cohort of skin melanoma patients that were treated with an
anti-PD-1 therapeutic antibody (Hugo et al., 2016). The majority
of CG-genes that RESET found epigenetically enhanced in mel-
anoma were more highly expressed in patients that either
completely (CR) or partially (PR) responded to therapy than in pa-
tients with a progressive disease (PD) (Figure 5F). Moreover, an
mRNA expression signature comprising an extended set of
CG-genes (Almeida et al., 2009) (CG-signature) was associated
with beneficial responses to anti-PD-1. Indeed, complete re-
sponders exhibited significantly higher values of the CG-signa-
ture than non-responding patients (p = 0.017, Figure 5G), and
patients stratified based on this signature had significantly
different overall survival (Figure 5H). Vice versa, in skin mela-
noma patients treated with another immune-checkpoint inhibi-
tor, anti-CTLA4 (Van Allen et al., 2015), high CG-scores were
associated with worse prognosis, even though not reaching sta-
tistical significance (Figure S5C). Recently, expression of the
CG-antigen MAGE-A was found predictive of resistance to
anti-CTLA4, but not to anti-PD1 (Shukla et al., 2018). Together,
these results warrant further investigations on the prognostic
value of CG-genes expression for patients treated with immune
checkpoint inhibitors.
Aberrant DNA Methylation in Pediatric Tumors
Pediatric tumors typically display a low mutation burden (Law-
rence et al., 2013), and their pathogenesis have been frequently
associatedwithspecificalterations inepigenetic regulatorymech-
anisms (McKenna and Roberts, 2009). Therefore, we explored
the potential of using RESET to investigate aberrant DNAmethyl-
ation in pediatric cancer. Recently, the NCI’s Therapeutically
Applicable Research to Generate Effective Treatments (TARGET)
initiative has profiled a large cohort of Wilms tumors, the most
common form of kidney cancer in children (Gadd et al., 2017).
This cohort included 84 favorable histology cases that relapsedncing Events
axis) for epigenetically silenced genes. GO categories are color-coded based
al regulation.
ally enhanced genes. GO categories are color-coded based on 3 main groups:
ated by cancer type. Silenced targets include several genes with mitochondrial
e), promoters of H2O2 degradations (light blue), components of the electron
al categories that group most of the epigenetically silenced genes shown in (C).
ressed in the presence of H2O2 and a gene expression signature composed of
ures are significantly anti-correlated (linear fit q-value on the y axis) in almost all
ce of epigenetic silencing of mitochondrial ROS inhibitors).
x axis) in melanoma patients responding versus non-responding to anti-PD-1
- and CG-like genes were tested if they were found epigenetically enhanced by
an independent skin melanoma patient cohort that underwent treatment with
of expression values in responders (CR and PR) minus the sum of expression
ssive disease (PD, gray dots) or exhibiting a partial response (PR, red contoured
rtitioned in two groups based on their CG signature scores with patients having
ith low scores (score <0.5, gray line).
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Figure 6. Aberrant DNA Methylation in Pediatric Wilms Tumors
(A) Percentage of probes for each tumor sample that are hyper- (x axis) and hypo-methylated (y axis). Tumor samples are color-coded based on their histological
subtype: favorable histology (FHWT, black contoured dots) and diffuse anaplasia (DAWT, black filled dots).
(B and C) Distribution comparison of the percentage of hypo- (B) and hyper-methylated (C) probes between the two histological subtypes (Wilcoxon test).
(D) Map overview of selected genetic and epigenetic alterations in Wilms tumors. Columns are tumor samples and each row is one selected alteration including
epigenetic silencing (blue contoured bars) and enhancing (red contoured bars) events, copy number amplifications (red bars), and somatic mutations (green
squares).Wild-type cases are in gray. Two separatemaps are generated for FHWT andDAWT cases. The alteration frequencies of each event in the two subtypes
are compared by taking the difference between the percentage of altered DAWT cases (%DA) and the percentage of altered FHWT cases (%FH) (bar plot, black
(legend continued on next page)
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(FHWT) (Figure S6A) and 42 cases characterized by diffuse
anaplasia (DAWT) and associated with unfavorable prognosis
and TP53mutations (Figure S6B).
UsingRESET,we first estimated the extent of hyper- and hypo-
methylation in these tumors (RESET-step 1). DAWT and FHWT
had comparable extent of hypo-methylation (Figure 6A), but
DAWTexhibitedsignificantlyhigherhyper-methylation (Figure6B)
and combined percentages of hyper and hypo-methylated TSS
probes indicated that these tumors exhibited DMI (Figure 6C).
Concordantly, epigenetic silencing and enhancing events
(RESET-step 2, Table S6) were in general more frequent in
DAWT cases that in FHWT (Figure 6D) and affected genes
involved in nuclear factor kB (NF-kB) and AKT-signaling as well
as apoptosis, DNA repair, cell metabolism, and cell proliferation
(Figure6D). Inparticular,we found that virtually all casesexhibited
hypo-methylation of theMYCN oncogene, sometimes concomi-
tant with copy number amplifications or somatic mutations.
MYCN has been reported as frequently upregulated in Wilms tu-
mors and altered through different mechanisms (Williams et al.,
2015). Our results indicate that hypo-methylation of this locus is
a hallmark of this tumor type.
Given that the unfavorable prognosis subtype, DAWT, had an
overall higher incidence of epigenetic events than tumors with
favorable histology (FHWT), we asked whether the occurrence
of epigenetic alterations was associated with worse outcome in
FHWT.Epigenetic silencingofTNFRSF10D,TRIP4, andNMRAL1
(FigureS6C)wasassociatedwith significantlyworsesurvival (Fig-
ures 6E–6G). BecauseTNFRSF10D andTRIP4 almost always co-
occurred with silencing of NMRAL1, we tested whether they had
independent prognostic value. Interestingly, we found that FHWT
tumors exhibiting silencing ofNMRAL1 and of eitherTNFRSF10D
or TRIP4 had significantly worse outcome than NMRAL1-only
altered samples (Figure 6H). These targets have all been impli-
cated in NF-kB signaling (Degli-Esposti et al., 1997; Jung et al.,
2002; Lian and Zheng, 2009), making this pathway a candidate
driver of Wilms tumor development and progression.
DISCUSSION
Over the last decade, several large-scale cancer genomics
studies have explored and characterized the landscape of ge-
netic modifications across thousands of human tumors. The re-
sulting catalog of pan-cancer associated variants misses an
important second dimension represented by cancer-selected
epigenetic alterations. Here, we explored DNA methylation
changes occurring across 24 human cancers. Our results stem
from an approach, RESET, that couples the concept of aberrant
methylation calling with an unbiased and systematic identifica-
tion of silencing and enhancing events. To draw an analogycontoured bars are for negative values, i.e., %FH > %DA, black filled bars are fo
p value < 0.05) are indicated by a star. Pathway annotations for silencing and enha
and red dots for annotations of enhanced genes).
(E–G) Kaplan-Meier survival analysis comparing FHWT cases with epigenetic sile
type cases (gray curves). Altered and wild-type groups are tested for significant
(H) Kaplan-Meier survival analysis comparing FHWT cases with epigenetic silenc
cases with epigenetic silencing of NMRAL1 only (light blue curve), and wild-type
log-rank test (p values are reported).
See also Figure S6 and Table S6.with computational methods to analyze DNA sequencing, the
first step of our approach resembles somatic variant calling,
whereas the second step is analogous to the search for candi-
date functional mutations.
By focusing of both hyper- and hypo-methylation at gene TSS,
we could identify a class of tumors exhibiting both numerous hy-
per-methylated TSS and numerous hypo-methylated TSS. We
refer to this phenotype as DNA methylation instability or DMI.
In particular, we showed that tumor subtypes previously re-
ported exhibiting a CpG island methylator phenotype (CIMP)
are actually characterized by DMI. DMI was significantly associ-
ated with mutations of chromatin remodelers, strengthening a
link between histone and DNA methylation and suggesting that
both need to be considered to understand the impact of recur-
rent mutations of chromatin remodeling complexes in cancer
(Lu and Allis, 2017; Suva` et al., 2013).
By exploring the interplay between genetic and epigenetic alter-
ations, we found examples of functional convergence. Indeed,
silencing and enhancing events co-occurrent with IDH1 and
CTNNB1 mutations frequently affected genes involved in their
respective pathways: cell metabolism and Wnt-signaling.
Silenced and enhanced events were further enriched for genes
involved in apoptosis, transcriptional regulation, especially Zinc-
finger proteins, cell metabolism, and for CG antigens. Inhibitors
of mitochondrial ROS generation were frequently silenced across
multiple tumor types, potentially favoring survival signals in stress
conditions (Lo´pez-Otı´n et al., 2013). Interestingly, epigenetically
enhancedexpressionofCG-antigenswas significantly associated
with sensitivity to anti-PD-1, but not anti-CTLA4, in skin mela-
noma. In light of recent studies on the use of demethylating agents
in the clinic, these results lead to the suggestive hypothesis that
therapeutic reactivationofCG-antigenscouldpotentiate theeffec-
tiveness of the anti-PD1 checkpoint inhibitor (Siebenka¨s et al.,
2017), whereas it could be deleterious in combination with anti-
CTLA4 (Shukla et al., 2018), and offer cancer-specific targets to
therapeutic approaches based on T cells engineering.
The pilot study that we conducted on Wilms tumors demon-
strates the potential for using our approach to explore clinically
relevant epigenetic modifications in pediatric tumors. Pediatric
tumors typically harbor few genetic alterations and are mostly
associated with epigenetic abnormalities affecting their differen-
tiation potential. Accordingly, they may represent a particularly
relevant setting for systematic investigation of aberrant DNA
methylation patterns.
Finally, here, we explored modification of DNA methylation
with respect to normal tissues and associated with in cis
changes of gene expression. However, adjacent normal tissues
not necessarily represent a tumor’s cell of origin, and expression
changes might not be direct consequence of DNA methylationr positive values, i.e., %DA > %FH). Significant differences (Fisher’s exact test
ncing events are shown on the right (blue dots for annotations of silenced genes
ncing of TNFRSF10D (E), TRIP4 (F), or NMRAL1 (G) (blue curves) versus wild-
different survival by log-rank test (p values are reported).
ing of NMRAL1 and at least one of TNFRSF10D and TRIP4 (blue curve), FHWT
cases (gray curve). Each group pair is tested for significant different survival by
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changes and/or not be a necessary condition for DNA methyl-
ation changes to be functional (Widschwendter et al., 2007).
While functional investigations of specific targets will be
required to validate the cancer specificity and causal relation-
ships of epigenetic and transcriptional changes, DNA methyl-
ation signatures could be designed to infer the cell of origin of
different tumor subtypes enabling a more robust distinction be-
tween cancer-driven and cancer-predisposing events (Capper
et al., 2018).
Overall, DNA methylation constitutes a simple mechanism to
control gene function in both normal and malignant condi-
tions. Systematic investigations of how cancer cells exploit this
mechanism to deregulate specific targets and processes can
fill a major gap in our understanding of disease manifestation,
by capturing and functionally implicating cancer-associated
methylation events and exploiting the therapeutic opportunities
they offer.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines used in this study
All the human cancer cell lines used in this study (Breast Cancer cell lines: MDA.MB.453, HCC70, UACC.893,BT.20, BT.474; Lung
adenocarcinoma cell lines: NCI.H522, SW1573; Prostate adenocarcinoma cell lines: PC.3, DU.145, VCAP; Head and Neck squa-
mous carcinoma cell lines: FADU; Melanoma cell lines: CHL.1, A375) were purchased from ATCC (supplied by LGC Standards
GmbH, Wesel, Germany).
Cell culture and experimental conditions
The cell lines were treated according to their recommended medium (http://www.atcc.org/products?geo_country=us) and all the
culture media contained 10% FBS. For 5-Aza-20-deoxycytidine (5-AZAdC, A3656 Sigma) treatment, cells were plated at 105 cells/ml
in 100mm culture plate and allowed to attach and grow for 24 hours before the treatment.
5-AZAdC treatment
Cells were subjected to a 7-day treatment during which the medium was changed every day, and 5-AZAdC was added in aqueous
solution at a final concentration of 1mM.
RNA isolation and RT-PCR
mRNA extractions from cultured cell lines were performed with the QIAGENRNeasy kit (74106). Reverse transcription into cDNAwas
performed with PrimeScript RT Master Mix (Takara Bio Europe SAS). RT-PCR was carried out with probes designed according to
PrimerBank database (https://pga.mgh.harvard.edu/primerbank/index.html) and synthesized by Microsynth AG, Balgach,
Switzerland.
Primers
PXMP4 Frw Primer: ACCTGGCACGGTTTGTGTT
PXMP4 Rev Primer: CCACCTGGGTTCAGGGATG
SYCP2 Frw Primer: TTCTGCTGGTCATACATGATGTC
SYCP2 Rev Primer: GAACAAATGCGAGGTACGAAAC
PNLDC1 Frw Primer: GGCAGGTCTGGACATAGAGTT
PNLDC1 Rev Primer: CGGGTCTTTAGATACCACTCCG
H2AFJ Frw Primer: ACGAGGAGTTAAACAAGCTGC
H2AFJ Rev Primer: TCATTTGCTCTTCGTCTTCTGAC
GAPDH Frw Primer: GGAGCGAGATCCCTCCAAAAT
GAPDH Rev Primer: GGCTGTTGTCATACTTCTCATGG
All RT-PCR reactions were performed in triplicates using the 7900HT Fast RT-QPCT System (Applied BiosystemsTM), and the
results were normalized to the housekeeping gene GAPDH.e2 Cell Reports 25, 1066–1080.e1–e8, October 23, 2018
METHODS DETAILS
Data collection
TCGA cohort data collection
Molecular and clinical data for 24 tumor types profiled by The Cancer Genome Atlas (TCGA) consortium were collected in July 2017
from FireHose (https://gdac.broadinstitute.org/) and cBioPortal (http://www.cbioportal.org/) (Cerami et al., 2012) data repositories.
Only the data publicly available at that time were used in our study (Table S1). The dataset includes somatic point mutation (whole
exome sequencing), copy number changes (Illumina SNP6 array), gene expression profiling (Illumina HiSeq, RSEM normalized
counts), and DNA methylation data (Illumina Infinium array). DNA methylation data were generated by Infinium HM450 array
(485,577 CpG site targeting probes), except for the ovarian cancer cohort that was analyzed with the Infinium HM27 array (27,578
CpG site targeting probes). All data was generated and processed by The Cancer Genome Atlas research network as described
in the corresponding manuscripts (see Table S1). The latest update regarding tumor types and subtype annotations were taken
from (Sanchez-Vega et al., 2018).
TARGET cohort data collection
Molecular and clinical data for the cohort of Wilms tumors were collected from TARGET initiative website (https://ocg.cancer.gov/
programs/target/data-matrix). It includes somaticmutation (whole exome sequencing andwhole genome sequencing), copy number
changes (Affymetrx 6.0 SNP arrays), gene expression profiling (Illumina HiSeq, RPKM normalized counts), and DNAmethylation data
(Illumina InfiniumHM450 array). Methods, including data generation and processing, and validate somatic mutations used in Figure 6
were reported in Gadd et al. (2017).
Other datasets
DNAmethylation and mRNA expression data for the cancer cell lines used in this manuscript (Figures 3F–3I and S3D–S3H) were ob-
tained from the GDSC database (https://www.cancerrxgene.org) and Gene Expression Omnibus (GEO): GSE32323, GSE29060, and
GSE5816. mRNA expression values for normal tissue samples (Figure S5A) was obtained from the GTEx database (http://gtexportal.
org/home/datasets). Genetic alterations (somatic point mutations, copy number amplifications and deletions) and the list of 505
recurrent events used in the enrichment had been previosly derived from the same TCGA datasets used in this manuscript (Mina
et al., 2017). Genome annotations used for the methylation probes characterization (Figures S1C–S1E) was obtained from UCSC
Genome Browser (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/).
DNA methylation probe selection and analysis
DNA methylation probe selection
Probes were further filtered to include only those mapping to TSSs including both canonical TSS within 50UTRs and unconventional
exonic TSS, as defined by cap analysis of gene expression (CAGE) by the FANTOM5 consortium (Forrest et al., 2014) (Table S2 and
Figure S1A). The genomic intervals flanking the TSSs (300 nt upstream to 300 nt downstream) were considered as gene promoter
regions (Figure S1A). Only probes mapping to a gene promoter region were considered in the downstream analysis.
Analysis of DNA methylation probe distribution
Probed loci were mapped to the canonical isoform of the corresponding gene according to FANTOM annotations or genomic prox-
imity to generate unique location distributions. Probes genomic locations were characterized by defining 7 classes: 1) upstream: up
to 1kb upstreamof the TSS, 2) 50UTR: interval between the TSS and coding start site, 3) exonic: inside the exons, 4) intronic: inside the
introns, 5) 30UTR: interval between coding end site and transcription end site (TES), 6) downstream: up to 1kb downstream of TES, 7)
intergenic: more than 1kb upstream or more than 1kb downstream of the TSS or TES, respectively. We manually verified that all
probes corresponding to silenced and enhanced genes identified by RESET and classified as intergenic were actually mapping to
non-canonical isoforms, hence the ‘‘intergenic’’ category has been renamed to ‘‘non-canonical’’ for these distributions. The set of
selected TSS probes included themajority of probes less than 1KB upstream or at 50UTR of the canonical isoform of the correspond-
ing gene, whereas only a minor fraction was downstream (< 1KB) or within the 30UTR of the canonical isoform (Figure S1C). Selected
probes that fell within the gene body were preferentially exonic, rather than intronic, despite the latter type was overall more frequent
(Figure S1C). Probes associated with silenced and enhanced targets followed the same distribution (Figures S1D and S1E). Overall,
less than 1% of the selected probes mapped to Alu and LINE-1 repeats.
The RESET algorithm
RESET analyzes large-scale DNA methylation sample cohorts to (i) test for the presence of aberrant DNA methylation at gene TSS
and (ii) assess whether aberrant methylation states lead to epigenetic silencing or enhancing of gene expression. RESET is based on
four steps: 1) probe selection and modeling, 2) aberrant methylation states analysis, 3) epigenetic silencing and enhancing (ESE)
score evaluation, and 4) statistical significance analysis of the ESE scores. The output consists of (i) sample-level methylation states
for each probe mapping to a gene promoter, i.e., normal, hyper-methylated, or hypo-methylated, and (ii) the collection of silencing
and enhancing events with a statistically significant effect on gene transcription. A schematic representation of the pipeline is shown
in Figures 1A and 3A.
Input data
RESET requires methylation data of both normal and tumor samples (unmatched), and transcriptomic profiles of the tumor samples.
Additionally, a map between DNA methylation array probes and gene TSS must be provided.Cell Reports 25, 1066–1080.e1–e8, October 23, 2018 e3
Step 1: Probe selection and modeling of DNA methylation in normal samples
In bisulfite-genomic DNA sequencing analysis, the extent of DNAmethylation in a CpG locus is reported as the ratio of the number of
methylated probedmolecules over the total number of probedmolecules. These ratios assume values between 0 and 1, can be char-
acterized by a b-distribution and are thus referred to as b-values. Actual b-values for all probes in our dataset followed a bimodal
distribution with modes in the low (< 0.1) and the high (> 0.8) extremes of the possible range. To ensure changes of DNA methylation
in cancer samples are not due to the expected variability of DNA methylation measured at a specific locus, RESET discards probes
with high variability in normal samples (Figure S2B), and defines two probe sets:
1. Low DNA Methylation probes: probes with mean b-values lower than 0.1 and standard deviation lower than 0.005 in normal
samples.
2. High DNA Methylation probes: probes with mean b -values higher than 0.8 and standard deviation lower than 0.005 in normal
samples.
RESET then uses these sets of DNA methylation probes with consistent status across normal samples to infer the expected
distribution of values at each locus (probe specific distribution) and at all loci with the same status, i.e., either low or high DNAmethyl-
ation (probe set distribution). The density function of a beta distribution is described by the two positive parameters, a and b:
fðx;a;bÞ= x
a1ð1 xÞb1
Bða;bÞ ;
where Bða;bÞ=GðaÞGðbÞ=Gða+ bÞ and G(z) is the gamma distribution. To determine both probe specific and probe set distributions,
RESET estimates the a and b parameters for each probe x from the observed mean and variance of beta values observed in normal
samples, according to the following formulas:
Meanx =
a
a+ bVarx =
ab
a+ bð Þ2 a+ b+ 1ð Þ:
The R library MASS to fit the global beta distribution models to the methylation beta values. The parameter space of the estimated
b-distributions in cancer samples for our set of selected probes is consistent with peaked distributions around 0 for probes with low
methylation in normal samples and around 1 for probes with high methylation in normal samples (Figures S1F–S1H).
Step 2. Methylation status analysis
To evaluate the DNA methylation status of a probe in a tumor sample, RESET compares its b-value to the probe specific and probe
set distributions estimated in step 1. A probe x with methylation value y in a specific sample is considered hyper-methylated if the
following conditions are met:
x ˛ Low DNA methylation probe setCDFxprobe specific b distributionðyÞR0:995CDFLowprobe set b distributionðyÞR0:995
where CDF is the cumulative density function of the distribution fitted in step 1.
Similarly, a probe x with methylation value y is considered hypo-methylated if
x ˛ High DNA methylation probe setCDFxprobe specific b distributionðyÞ%0:005CDFHighprobe set b distributionðyÞ%0:005
The output of this step is a discrete description of the DNAmethylation state of each probe in each tumor sample, where a probe can
be normal-methylated, hyper-methylated, or hypo-methylated, with the latter two also defined as aberrant DNA methylation states.e4 Cell Reports 25, 1066–1080.e1–e8, October 23, 2018
Step 3. Epigenetic silencing and enhancing score
After determining the methylation status of each probe in each tumor sample, RESET evaluates the effect of aberrant DNA methyl-
ation states on gene transcription. Specifically, RESET quantifies the associations between hyper- (hypo-) methylation of a probe p
and a significant decrease (increase) ofmRNA expression of the gene gwhose TSSmaps to p. In all the analyses that follow, RNA-seq
RSEM normalized counts have been rank transformed using a qq-normalization (R function qqnorm). To evaluate the association
between DNA methylation and gene transcription, we defined a score as the product of two distances: the centroid distance and
the rank distance.
The Centroid Distance (CD) is meant to capture the global difference in gene expression between tumor samples where a probe is
hyper-/hypo-methylated (altered samples) and tumor samples where the probe is normal-methylated (wild-type or WT samples). CD
is defined as the geometric mean of the centroids of altered and wild-type tumor samples in the 2D space defined by the b-values (x)
of p and mRNA expression values (y) of g across all the samples:
CDp =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
jcentroidðxWTÞ  centroidðxalteredÞj3 jcentroidðyWTÞ  centroidðyalteredÞj
p
RNA-seq qq-transformed values are here rescaled to the [0,1] interval to be within the same range of values as beta values.
The Rank Distance (RD) is designed to evaluate the inverse correlation between DNA methylation and mRNA expression. Here,
samples are first binned into four classes (B1-4) according to their beta values falling within the intervals: [0,0.25], (0.25,0.5],
(0.5,0.75], and (0.75,1]. In an ideal situation, where gene expression is perfectly anti-correlated with DNAmethylation values, all sam-
ples in the bin i have lower mRNA expression values than samples in bin i-1 and higher mRNA expression values than samples in bin
i+1. Formally, if Nk; k ˛ f1;2;3;4g, is the number of samples in bin k, rs the ranking of sample s according to its expression level (from
higher to lower) and bsthe ideal bin [1-4] to which s is assigned based on its DNA methylation value, then:
rs ˛ ½1; N1c s jbs = 1rs ˛ ½N1 + 1; N1 +N2c s jbs = 2rs ˛ ½N1 +N2 + 1; N1 +N2 +N3c s jbs = 3rs ˛ ½N1 +N2 +N3 + 1; N1 +N2 +N3 +N4c s jbs = 4
Note that the rank of samples within a bin is irrelevant. The Rank Distance quantifies the distance of the observed associations be-
tween rs and bs for all samples s from the ideal scenario just described and it is defined as follow:
RDp =
X4
k= 1
 
1+
jIk j
Nk +a

PjOk j
i= 1
bi  bi 
Nk +a
!
;
where Ik is the set of samples in Bk when Bk corresponds to their ideal bin ðbi = biÞ, whereas Ok is the set of samples in Bk when Bk is
not their ideal bin ðbisbiÞ. Finally, a positive constant is added to the denominator of each component, to limit the variance of RD
when Nk is small. In this study we set a = 4.
Step 4. Statistical significance analysis
To determine the significance of the observed scores, we adopted the strategy previously proposed in the Significance Analysis of
Microarrays (SAM) (Tusher et al., 2001). This technique is based on a permutation of the observed data to estimate the false discovery
rate (FDR) associated to a significance threshold of themeasured effect size. Precisely, for a threshold t, the number of False Positive
(FPt) out of the observed number of measurements exceeding t (set of positive solution or Pt) is estimated as the average number of
measurements exceeding t after multiple random permutations of the input values, and the FDR of t is defined as:
FDRt =
FPt
Pt
:
In our analysis, Pt is determined by counting the number of probes that obtain a score higher than a given threshold t. To permute the
expression data, we pooled the normalized expression values of all genes in samples belonging to the same DNAmethylation bin Bk,
with k = 1,2,3,4. The distributions of normalized mRNA expression values in each bin confirmed an overall inverse correlation be-
tween DNA methylation and mRNA expression (data not shown). For a given probe p and sample s, the corresponding expression
value is then sampled from the pool corresponding to the bin associated to s (bs). Once expression values are sampled for all sam-
ples, the score of p is re-computed. We repeat this process 100 times to generate 100 random distributions of scores and from these
distributions we determine FPt as described above. The smallest t that guarantees an FDR < 0.1 in all our analyses is chosen as the
significance cut-off threshold t*, and genes matched to probes with a score greater than t* are considered as epigenetically silencedCell Reports 25, 1066–1080.e1–e8, October 23, 2018 e5
(if p is a hyper-methylated probe) or epigenetically enhanced (if p is a hypo-methylated probe). In this work, we additionally required
the score to be always greater than 1.5, to guarantee a minimum effect size.
Comaprison of RESET to other methods
Previous approaches to identify epigenetically silenced and enhanced genes had been based either on defining altered and not-
altered samples based on an arbitrary b-value threshold (hyper-methylated if b-value > 0.3, hypo-methylated if b-value < 0.1) and
then testing the two groups for differential expression (Hinoue et al., 2012; Cancer Genome Atlas Network, 2015), or on identifying
significant anti-correlation between b-values andmRNAexpression (Sepulveda et al., 2016). Independently of the adopted test, com-
mon pitfalls of all these methods are that their results are invariably dependent on the alteration frequency, and, for large cohorts,
highly significant p values can be obtained even for small effect sizes, leading to large numbers of significant hits even after correction
for multiple testing (Tusher et al., 2001). As an example, we implemented and applied thesemethodologies to the luminal breast can-
cer cohort and test all genes for epigenetic silencing. Independently of the adopted test, they all show a string dependency with alter-
ation frequency and return more than 1,000 significant hits with an FDR < 0.01 (Figure S3A). Overall, these methods rank candidate
silenced and enhanced genes based on the obtained p value, even though altered and non-altered sample sets have variable sizes
that depend on the gene being tested. As a consequence, genes altered in 50% of the cases will be more likely to be top scoring
because their sample size guarantees the maximum statistical power (Figure S3A). This is exemplified by computing the best
possible p value of aWilcoxon test as a function of the size of the altered sample set (Figure S3B). In contrast, RESET put an emphasis
on the strength (or effect size) of the inverse association betweenDNAmethylation andmRNA expression, here defined by the RESET
score, and it directly estimates the false discovery rate associated with specific scores to determine a significance threshold. Impor-
tantly, this score is independent of the alteration frequency and sample size (Figure S3C). For completeness, t test andWilcoxon test
based analyses were repeated using the methylation calls generated by the step 1 of RESET, yielding similar results. The method-
ologies were run on both the FPKM/RSEM normalized count data and the qq-normalized gene expression. We should note that the
use of t test with RSEM values or log-transformed RSEM-values should be avoided given the non-normal distribution of these data.
To evaluate the performance of RESET and other conventional methods using experimental models, we exploited publicly avail-
able RNA sequencing datasets regarding cell lines treatedwith 5-AZAdC (Figure S3E). Methylome data for non-treated cell lines were
also downloaded fromGDSC database. First, for each cell line, we obtained a list of reactivated genes upon 5-AZAdC treatment. For
gene x to be considered as reactivated, it needed to be hypermethylated in non-treated condition (average beta-value of all probes
mapping to gene x TSS be larger than 0.7), and have expression fold-change bigger than 1.5 (5-AZAdC treated versus non-treated).
Second we applied all the methods to the cell lines’ tissue-of-origins in TCGA cohort (CRC and LUAD), and derived the silenced
genes proposed by each method. Percentage of reactivated genes for each cell line/method was obtained by intersecting the list
of reactivated gene in each cell line and the silenced genes proposed by each method (Figure S3E).
Application of RESET to the pan-cancer TCGA dataset
In this study, we ran RESET on the pan-cancer TCGA dataset considering the 170,953 probes that map to FANTOM5 TSSs. Given
that only 14 tumor types have DNA methylation data available for normal tissue samples (BLCA, BRCA-Basal, BRCA-Non Basal,
CRC, ESCA, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PRAD, THCA, UCEC), we defined a set of pan-cancer probes including
only the probes consistently classified as Low (or High) DNA methylation probes across all normal tissues available. The results pre-
sented in the manuscript were obtained by running RESET separately on each tumor type using the pan-cancer probe set. For tumor
types without methylation data for normal samples, the pool of normal samples from the all tissue types was used to build the refer-
encemethylationmodels. The aggregated set of pan-cancer epigenetic silencing and enhancing events was taken as the union of the
results from each tumor type. Aberrant DNAmethylation at genes scoring as significant in at least one tumor type was re-assessed in
all cohorts, and each gene was considered as significant in all cohorts where the score was greater than 1.5. Finally, RESET was also
run on each individual tumor type using all the probes (not only the pan-cancer probe set) selected at Step 1 based on the corre-
sponding normal tissue samples (when available). These results thus include tissue-specific methylation events, i.e., silencing and
enhancing of genes whose methylation status is tissue-dependent. While the discussion of these results is beyond the scope of
this manuscript, all results are made available at http://ciriellolab.org/reset/reset.html.
Application of RESET to the TARGET dataset
The Wilms tumor cohort did not include methylation data for normal samples, hence we used for this analysis the previously-defined
pan-cancer Low (or High) DNA methylation probe sets. Moreover, the pool of normal samples used in TCGA dataset for the tumors
without normal methylation data was used to build the reference methylation models. In this analysis, enhancing events were
selected with a score associated to FDR < 0.1.
QUANTIFICATION AND STATISTICAL ANALYSIS
All the statistical analyses described in this section were performed with R.
Association between genomic alterations and percentage of hyper/hypo methylated probes
We tested whether recurrent genomic alterations (Mina et al., 2017) are enriched on samples with a higher percentage of hyper/hypo
methylated probes, separately for each individual tumor type. The Wilcoxon’s rank-sum test (one sided) was used in the individual
tumor type analysis, contrasting wild-type and altered samples. The same procedure was applied to test the enrichment of tumore6 Cell Reports 25, 1066–1080.e1–e8, October 23, 2018
subtypes among samples with high fraction of hyper-/hypo-methylated probes (Figures 1B–1D). P values were corrected formultiple
hypothesis testing with the Benjamini-Hochberg method.
DNA Methylation Inversion (DMI) score calculation and genomic alteration enrichment in DMI samples
The DMI score, designed with the aim of capturing the concomitant increase in both hyper- and hypo-methylation events, is defined
as the Fb-measure) of hyper- (H) and hypo- (h) methylation frequencies:
DMI=

1+ b2
 Hh
b2H+ h
:
We used b = 2 in our analyses, to compensate for the asymmetric distribution of hyper- and hypo-methylation frequencies. The
enrichment of each genomic alteration on samples with high DMI score was studied both within each individual tumor type and at
pan-cancer level. The Wilcoxon’s rank-sum test (one sided) was used for the individual tumor type analyses, contrasting wild-
type and altered samples. For the pan-cancer analysis we perfomed a type II ANOVA analysis separately for each genomic alteration,
testing only alterations with at least 4 occurrences. The alteration occurrence in each sample was used as binary independent var-
iable, whereas the DMI score was used as dependent variable. For the pan-cancer analysis we considered tumor type as co-factor,
and for each particular alteration x, the tumor types with no occurrence of the alteration x were excluded from the ANOVA analysis.
P values were corrected for multiple hypothesis testing with the Benjamini-Hochberg method.
Association between genomic alterations and epigenetic silencing and enhancing events
We performed enrichment analysis of genomic alterations at two different levels: global and event-specific. In the global analysis, we
sought to understand whether specific genomic alterations were enriched in samples with high epigenetic silencing or enhancing
events. In this case we repeated the enrichment analysis performed for the hyper/hypo methylated probes, described above. The
analysis was performed separately on each single tumor type, using the same procedure, detailed above, for testing the enrichment
of genomic alterations in DMI samples.
For the event-specific analysis, instead, we identified the patterns of co-occurrence and mutual-exclusivity between individual
epigenetic silencing and enhancing events identified by RESET and the set of 505 recurrent cancer-associated genetic alterations,
using the SELECT algorithm (Mina et al., 2017). The analysis was performed in a pancan fashion, considering all the tumor samples
together and using tumor type and subtype as covariates of the SELECT analysis to remove tumor type effects.
Estimation of samples’ purity, cell type composition, chromosomal instability and stemness score: the following datasets/pipelines
were used to evaluate different qualities of tumor samples:
d ABSOLUTE (Carter et al., 2012): estimation of samples purity and ploidy.
d EPIC (Racle et al., 2017): estimation of immune cells infiltration
d xCell (Aran et al., 2017): estimation of immune, microenvironment, and stroma scores
d Chromosomal instability was measure with (i) the number of amplified and deleted segments in each sample (normalized copy
number value > 0.3, segment count), and (ii) the percentage of genes amplified or deleted (fraction AMP/DEL genes). The
segment file from the TCGA Pan-Cancer Atlas cohort and the discrete gene-level copy number changes derived by GISTIC
were used as input data.
d Stemness signatures were derived using a dataset provided in Malta et al. (2018).
Association between EPIC cell type composition and epigenetic silencing and enhancing events
Associations between epigenetic silencing and enhancing events and immune cell type composition estimated by EPIC were tested
on each individual tumor type. For each epigenetic event, EPIC scores in altered samples were compared to score in non-altered
samples by Wilcoxon one-tail test. P values were corrected for false discovery rate using the Benjamini-Hochberg procedure. Asso-
ciations were considered significant if the obtain a q value < 0.1 and altered samples had score at least 1.5 fold higher than non-
altered samples.
Gene Ontology (GO) Terms enrichment analysis
GO Terms enrichment analysis was performed using the online webservice based on the Molecular Signatures Database (MSigDB)
(http://software.broadinstitute.org/gsea/msigdb/index.jsp). Enriched GO terms were defined as GO biological process (BP) and
molecular function (MF) terms obtaining a FDR-adjusted P value < 0.01, retreiving a maximum of 100 terms.
Gene expression signature enrichment analysis
Single sample Gene Set Enrichment analysis (Barbie et al., 2009) (ssGSEA), implemented in the R package GSVA, was used to calcu-
late an expression score for each gene expression signature and each sample. The default parameters from the GSVA package were
used. In this study, we used the following gene signatures:
Mitochondrial-ROS: GPX1, IVD, HSD17B4, ACADS, DECR1, CPT1A, CROT, PECI, NUDT19, ETFB, ALDH7A1, AASS, CYB5A,
PECR, HSD17B8, NNT, ALDH1B1, CYB5R1, UQCRH, PRDX1, AIFM2, ALKBH3, P4HTM, CYB561, SCCPDH, TXNRD2.Cell Reports 25, 1066–1080.e1–e8, October 23, 2018 e7
H2O2-signature: PCF11, TMEFF1, NRIP1, SERPINB9, EFNB2, OXTR, ATP6V0E1, ATRX, LUC7L3, SUV420H1, PTPRO, SCAMP1,
SP100, SOCS5, THAP10, YTHDC2, FLRT3, RAB2A, C1orf103, HOMER1, MYBL1, BAALC.
CG-signature: ACRBP, ACTL8, ADAM2, ADAM29, AKAP3, AKAP4, ANKRD45, ARMC3, ARX, ATAD2, BAGE, BAGE2, BAGE4,
BAGE5, BRDT, CABYR, CAGE1, CALR3, CASC5, CCDC110, CCDC33, CCDC36, CCDC62, CCDC83, CEP290, CEP55,
COX6B2, CPXCR1, CRISP2, CSAG1, CT45A1, CT45A3, CT45A4, CT45A5, CT45A6, CT47A1, CT47A10, CT47A11, CT47A2,
CT47A3, CT47A4, CT47A6, CT47A7, CT47A8, CT47B1, CTAG1A, CTAG1B, CTAG2, CTAGE1, CTAGE5, CTCFL, CTNNA2,
DCAF12, DDX43, DDX53, DKKL1, DMRT1, DNAJB8, DPPA2, DSCR8, ELOVL4, FAM133A, FAM46D, FATE1, FBXO39, FMR1NB,
FTHL17, GAGE1, GAGE12B, GAGE12C, GAGE12D, GAGE12E, GAGE12F, GAGE12H, GAGE12I, GAGE12J, GAGE13, GAGE2A,
GAGE4, GAGE5, GAGE6, GAGE7, GAGE8, GPAT2, GPATCH2, HORMAD1, HORMAD2, HSPB9, IGSF11, IL13RA2, KIAA0100,
LDHC, LEMD1, LIPI, LUZP4, LY6K, MAEL, MAGEA1, MAGEA10, MAGEA11, MAGEA12, MAGEA2, MAGEA2B, MAGEA3,
MAGEA4, MAGEA5, MAGEA6, MAGEA8, MAGEA9, MAGEB1, MAGEB2, MAGEB3, MAGEB4, MAGEB5, MAGEB6, MAGEC1,
MAGEC2, MAGEC3, MORC1, NLRP4, NOL4, NR6A1, NXF2, NXF2B, ODF1, ODF2, ODF3, ODF4, OIP5, OTOA, PAGE1,
PAGE2, PAGE2B, PAGE3, PAGE4, PAGE5, PASD1, PBK, PIWIL2, PLAC1, POTEA, POTEB, POTEC, POTED, POTEE, POTEG,
POTEH, PRAME, PRM1, PRM2, PRSS54, PRSS55, RBM46, RGS22, ROPN1, RQCD1, SAGE1, SEMG1, SLCO6A1, SPA17,
SPACA3, SPAG1, SPAG17, SPAG4, SPAG6, SPAG8, SPAG9, SPANXA1, SPANXA2, SPANXB1, SPANXC, SPANXD, SPANXN1,
SPANXN2, SPANXN3, SPANXN4, SPANXN5, SPATA19, SPEF2, SPO11, SSX1, SSX2, SSX2b, SSX3, SSX4, SSX4B, SSX5, SSX6,
SSX7, SSX9, SYCE1, SYCP1, TAF7L, TDRD1, TDRD6, TEKT5, TEX101, TEX14, TEX15, TFDP3, THEG, TMEFF1, TMEFF2,
TMEM108, TMPRSS12, TPPP2, TPTE, TSGA10, TSPY2, TSPY3, TSSK6, TTK, TULP2, VENTXP1, XAGE1B, XAGE1E, XAGE2,
XAGE3, XAGE5, ZNF165, ZNF645.
Correlation Analysis between gene expression signatures
To evaluate the degree of correlation between two signature scores in the tumor samples, we used the R ‘‘cor’’ function to retrieve the
Pearson correlation coefficient. To estimate the significance of the correlation value, we used R ‘‘lm’’ function to fit a linear model and
retrieve the corresponding FDR-adjusted P values.
Survival analysis
Kaplan–Meier survival analysis was used to assess the relationship of the signature scores with overall survival. We applied the Cox
proportional hazard model for multivariable analysis, to determine the associations between predictor variables and to obtain
adjusted hazard-ratios. These analyses were performed with the R package ‘‘survival.’’
DATA AND SOFTWARE AVAILABILITY
The R implementation of the RESET algorithm, the processed TCGA data and the results of the RESET analysis are publicly available
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